Building Bayer For The Next Decade And Navigating A Patent Cliff

In Leverkusen, Germany, following Bayer AG's full-year 2018 earnings presentation in February, In Vivo sat down with Stefan Oelrich to discuss his first impressions since taking on the head of pharma role last year, the company’s approach to collaboration and externalization of research, and what Bayer will look like midway through the 2020s when it will hit a major patent cliff.

Bayer has around 50 projects in clinical development, with key novel compounds coming forward in the next few years that...